Navigation Links
Open Letter to Speaker Pelosi on Approval of Mental Health Parity
Date:3/11/2008

SAN DIEGO, March 11 /PRNewswire/ -- Dr. Fred Baughman released the following statement today:

Dear Madam Speaker,

Believing, with you, that "Illness of the brain must be treated like illness anywhere else in the body," the House of Representatives have passed a mental health parity bill. The problem is that there is no medical proof that psychiatric diagnoses are actual diseases, disorders or illnesses of the brain. Claiming they are, as purveyors of psychiatry and "mental health" assert, is the greatest health care fraud in U.S. history.

In fact, psychiatry is distinct from the rest of medicine in that they do not examine for, test for, or diagnose, physical abnormalities -- diseases.

Make no mistake: psychiatrists absent themselves from the medical profession the moment they enter their psychiatric training programs, and leave behind the tools with which to diagnose physical diseases, embracing, instead, interviews, behavior check-lists and their labeling-billing bible, the Diagnostic and Statistical Manual published by the American Psychiatric Association. Predictably, the Psychiatric Association's Manual of diseases has exploded from 112 mental disorders in 1952 to 374 in the 1994, DSM-IV.

By parroting the "disease" lie, psychiatry guarantees a never-ending supply of new "patients" made up of normals of all ages, while abrogating the informed consent rights of every one of them.

My specialty, neurology, is officially dedicated to the diagnosis and treatment of organic-physical diseases of the brain and nervous system. As a Fellow of the American Academy of Neurology, I have fought and lobbied to get its leaders to clarify for the public what a disease is and is not, to help educate the public and to help them educate themselves in the face of the ubiquitous "disease"-"chemical imbalance" lie.

I am appalled by the actions of the AAN, the American Medical Association, the American Academy of Pediatrics, and o
'/>"/>

SOURCE Fred A. Baughman Jr., MD
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Highlands Acquisition Corp. Receives Non-Compliance Letter From Amex
2. AHCA, Alliance Praise Bipartisan Johnson, Collins Letter Urging Rejection of Bush Medicare Cuts
3. Texas Health Care Association Asks Texas Congressional Delegation to Sign Letter Urging House Budget Committee to Rescind Bush Medicare Cuts
4. Whitemark Homes Signs Letter of Intent to Acquire Metiscan Holdings, Inc.
5. Public Health Officials Warn About the Unrecognized Health Hazards of Smoking from a Hookah, Reports the Harvard Mental Health Letter
6. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. Long Term Care Newsletter Helps Preserve Solvency & Sanity While Caring for Loved One
8. Tips for Troublesome Medications, From the Harvard Heart Letter
9. High Calcium Intake May Not Help Prevent Fractures, Reports The Harvard Health Letter
10. An Open Letter to 20/20 and the Shareholders of Premier Exhibitions, Inc.
11. Depression in the Elderly is Complicated but Treatable, From the Harvard Mental Health Letter
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 2Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 3Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 4CVS Caremark Names New Chief Human Resources Officer 2Emerson Ecologics Introduces the Emerson Quality Partner 28TM 29 Program 55830 1Emerson Ecologics Introduces the Emerson Quality Partner 28TM 29 Program 55830 2Archi Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull Through Reporting Capabilities 55826 1Archi Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull Through Reporting Capabilities 55826 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 1NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 3NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 4NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 5
Other Medicine Technology:Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 2Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 3Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 4Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7